Sign in
CompletedNo phase

Andexanet Alfa for Reversal of Factor Xa Inhibitors in Traumatic Brain Injury: A Retrospective Single-Centre Study

Key facts

Who runs it
University Medical Centre Ljubljana
Where
Slovenia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
34 people enrolled
Started
1 Aug 2024
Ended
16 Sept 2026
Type of study
Observational
Record updated
27 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥18 years
  • Traumatic brain injury with Glasgow Coma Scale score 7-15
  • Active treatment with a direct factor Xa inhibitor (apixaban, rivaroxaban)
  • CT-confirmed traumatic intracranial haemorrhage (intraparenchymal haemorrhage, subdural haematoma, epidural haematoma, subarachnoid haemorrhage, or combination)
  • Received andexanet alfa for anticoagulation reversal
  • Baseline and at least one follow-up CT scan available for comparison

Who cannot take part

  • Anticoagulation with agents other than direct factor Xa inhibitors (e.g., dabigatran, warfarin)
  • Concurrent use of other reversal agents (e.g., four-factor prothrombin complex concentrate) in the same treatment episode
  • Non-traumatic intracranial haemorrhage
  • Glasgow Coma Scale <7 or GCS 16 (i.e., GCS 3-6 indicating severe TBI or GCS 16 indicating no significant TBI)
  • No follow-up CT imaging available
  • Incomplete medical records precluding primary outcome assessment

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Elderly patients on direct oral anticoagulants (DOACs), specifically factor Xa (FXa) inhibitors such as apixaban and rivaroxaban are at elevated risk of haematoma expansion following traumatic brain injury (TBI). Andexanet alfa is a recombinant modified factor Xa decoy protein that directly reverses the anticoagulant effect of FXa inhibitors. The pivotal ANNEXA-4 single-arm trial reported hemostatic efficacy of approximately 82% in the overall cohort and 82.9% among patients with intracranial haemorrhage (ICH). The subsequent ANNEXA-I randomised controlled trial demonstrated 67.0% hemostatic efficacy with andexanet alfa compared with 53.1% in the usual-care group (adjusted difference 13.4 percentage points; p=0.003) among patients with spontaneous ICH. However, both landmark trials were focused predominantly on spontaneous ICH, and TBI-specific real-world data on andexanet alfa remain limited.

Read full original descriptionShow less

This retrospective single-centre cohort study evaluates the hemostatic efficacy and safety of andexanet alfa in adult patients with traumatic intracranial haemorrhage who were received FXa inhibitor anticoagulation. All patients had a baseline computed tomography (CT) scan and at least one follow-up CT within 24 hours of andexanet alfa administration. The primary outcome is the proportion of patients achieving excellent or good hemostatic efficacy, defined by the percentage change in haematoma volume (for intraparenchymal haemorrhage, IPH) or maximum thickness (for subdural haematoma, SDH; epidural haematoma, EDH; or subarachnoid haemorrhage, SAH) between baseline and follow-up CT: Excellent (≤20% increase), Good (21-35% increase), or Poor (>35% increase). Key secondary outcomes include 30-day all-cause mortality, thrombotic complications (deep vein thrombosis, pulmonary embolism, ischaemic stroke, myocardial infarction), reduction in anti-factor Xa activity, neurosurgical intervention rate, and hospital and ICU length of stay.

The group in the trial

  • Andexanet Alfa Recipients

    Adult patients (age ≥18 years) with traumatic brain injury (Glasgow Coma Scale 7-15) who were receiving a direct factor Xa inhibitor (apixaban, rivaroxaban) at the time of injury and who received andexanet alfa for reversal of anticoagulation following CT-confirmed traumatic intracranial haemorrhage at UMC ljubljana, Slovenia, \[2024-2026\]. All patients had a baseline CT scan performed prior to or shortly after andexanet alfa administration and at least one follow-up CT scan within 24 hours. The cohort includes patients with all subtypes of traumatic intracranial haemorrhage, including intraparenchymal haemorrhage, subdural haematoma, epidural haematoma, subarachnoid haemorrhage, or combinations thereof. Andexanet alfa was dosed according to the product labelling based on the specific FXa inhibitor, dose, and timing of the last dose.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Hemostatic Efficacy and Safety of Andexanet Alfa for Reversal of Factor Xa Inhibitor-Associated Intracranial Haemorrhage in Traumatic Brain Injury: A Retrospective Single-Centre Cohort Study
Record updated
27 October 2026